

July 1, 2019

Ono Announces Status of Acquisition of Own Shares

(Acquisition of own shares under the Articles of Incorporation pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Osaka, Japan, July 1, 2019 - Ono Pharmaceutical Co., Ltd. (President, Representative Director and CEO, Gyo Sagara; “the Company”) today announced that it has acquired its own shares pursuant to the provisions of Article 156 of the Companies Act, applied by replacing terms pursuant to the provisions of Article 165, paragraph 3 of the same Act. The status (progress report) of the acquisition is as follows.

Particulars

1. Class of shares acquired:	Common stock of the Company
2. Total number of shares acquired:	4,770,800 shares
3. Aggregate amount of acquisition cost:	9,299,863,650 yen
4. Period of acquisition:	June 1, 2019 to June 30, 2019 (execution base)
5. Method for acquisition:	Purchased on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution on May 30, 2019 by documents instead of resolution by board meetings

(1) Class of shares to be acquired:	Common stock of the Company
(2) Total number of shares to be acquired:	15 million shares (maximum) (2.92% of the total outstanding shares excluding treasury shares)
(3) Aggregate amount of acquisition cost:	¥30.0 billion (maximum)
(4) Period of acquisition:	May 31, 2019 to September 30, 2019

2. Accumulated Company’s own shares acquired through June 30, 2019, pursuant to the resolution by documents instead of resolution by board meetings

(1) Total number of shares acquired:	5,132,400 shares
(2) Aggregate amount of acquisition cost:	9,999,822,700 yen

Contact**ONO PHARMACEUTICAL CO.,LTD.**

Corporate Communications

Public_relations@ono.co.jp